secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001104659-25-045127
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.01, 5.02, 3.02, 4.01, 9.01, 3.03, 5.01, 5.03, 5.05, 5.06, 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma completes de-SPAC merger, receives $15M PIPE, begins Nasdaq trading
--------------------------------------------------------------------------------

- Closed de-SPAC merger with Iris Acquisition Corp; issued 17.5M shares at $10/share ($175M equity value) to Liminatus securityholders.
- Concurrent $15M PIPE investment (1.5M shares at $10) from accredited investor.
- Sponsor forfeited 4.18M private placement warrants; 59,844 public shares redeemed for ~$702k.
- Liminatus Pharma, a pre-clinical CD47 checkpoint inhibitor developer, reported FY2024 net loss of $3.5M, accumulated deficit $28.7M.
- Common stock (LIMN) and warrants (LIMNW) began trading on Nasdaq May 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/0001104659-25-045127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925045127/tm2513673d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer